年初至今恒生医疗保健指数表现靓丽。受到国内创新药BD(BusinessDevelopment)交易持续落地叠加国产创新产品出海预期影响,年初至今(截至25 年7 月16 日,下同),恒生医疗保健指数表现靓丽,港股恒生医疗健康指数收涨63.03%,跑赢恒生国企指数41.47pp。分子板块来看,港股医药子板块表现分化明显,SW 港股生物制品、化学制药、医疗服务、医疗器械、医药商业、中药等子板块年初以来...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.